Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens

L'enregistrement des médicaments du sida (un défi pour l'Europe)

TOURS-BU Sciences Pharmacie (372612104) / SudocSudocFranceF

The Innovative Medicines Initiative: an engine for regulatory science.

Since its launch in 2008, the Innovative Medicines Initiative has catalysed the formation of many consortia to address challenges in drug development and regulation. As it moves into its second phase, we highlight key outcomes so far and the lessons learned.info:eu-repo/semantics/publishe

The Energy Justice Tool Suite: an interdisciplinary and comprehensive method for energy transition territorialization: Special Session 25 "Smart cities and regions informing the energy transition"

International audienceWithin a French context of Energy Transition, the "Energy Justice Tool Suite" project aims at designing, experimenting and optimizing what we call an interdisciplinary and a comprehensive "tool suite" dedicated to energy justice. At the urban, technical and socioeconomic levels, the idea is to design a "tool suite" to characterize, assess, evaluate and co-construct an inclusive energy and socio-territorial justice-with the actors of these territories. This research is based on an interdisciplinary approach, combining engineering sciences with social and spatial sciences, in order to co-construct an inclusive territorialization of energy transition, leading to energy justice. For this purpose, the "Energy Justice Tool Suite" project aims at designing, not buildings archetypes, but multiscale energy complex systems archetypes: physical phenomena to design the energy poverty assessment model at the block scale, and human behaviour, within an empowering perspective, through the animation of learning workshops. This experiment will be conducted on two fields of observation: Grenoble-Alpes Métropole and the region of Compiègne, to establish a transect of energy poverty situations. The "Energy Justice Tool Suite" project also aims at designing, experimenting and optimizing a transversal tool to aid decision making and a tool to aid consultation making for energy and socio-territorial multiscale justice

The Energy Justice Tool Suite: an interdisciplinary and comprehensive method for energy transition territorialization: Special Session 25 "Smart cities and regions informing the energy transition"

International audienceWithin a French context of Energy Transition, the "Energy Justice Tool Suite" project aims at designing, experimenting and optimizing what we call an interdisciplinary and a comprehensive "tool suite" dedicated to energy justice. At the urban, technical and socioeconomic levels, the idea is to design a "tool suite" to characterize, assess, evaluate and co-construct an inclusive energy and socio-territorial justice-with the actors of these territories. This research is based on an interdisciplinary approach, combining engineering sciences with social and spatial sciences, in order to co-construct an inclusive territorialization of energy transition, leading to energy justice. For this purpose, the "Energy Justice Tool Suite" project aims at designing, not buildings archetypes, but multiscale energy complex systems archetypes: physical phenomena to design the energy poverty assessment model at the block scale, and human behaviour, within an empowering perspective, through the animation of learning workshops. This experiment will be conducted on two fields of observation: Grenoble-Alpes Métropole and the region of Compiègne, to establish a transect of energy poverty situations. The "Energy Justice Tool Suite" project also aims at designing, experimenting and optimizing a transversal tool to aid decision making and a tool to aid consultation making for energy and socio-territorial multiscale justice

Local wood (biomolecules) valorisation through the characterization and industrial production of Robinetin, a yellowish fluorescent colorant

National audienc

TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions

International audienceTissue factor pathway inhibitor-2 (TFPI-2) is a potent inhibitor of plasmin which activates matrix metalloproteinases (MMPs) involved in degradation of the extracellular matrix. Its secretion in the tumour microenvironment makes TFPI-2 a potential inhibitor of tumour invasion and metastasis. As demonstrated in aggressive cancers, TFPI-2 is frequently down-regulated in cancer cells, but the mechanisms involved in the inhibition of tumour progression remained unclear. We showed in this study that stable TFPI-2 down-regulation in the National Cancer Institute (NCI)-H460 non-small cell lung cancer cell line using specific micro interfering micro-interfering RNA promoted tumour progression in a nude mice orthotopic model that resulted in an increase in cell invasion. Moreover, TFPI-2 down-regulation enhanced cell adhesion to collagen IV and laminin via an increase in alpha(1) integrin on cell surface, and increased MMP expression (mainly MMP-1 and -3) contributing to cancer cell invasion through basement membrane components. This study also reveals for the first time that pulmonary fibroblasts incubated with conditioned media from TFPI-2 silencing cancer cells exhibited increased expression of MMPs, particularly MMP-1, -3 and -7, that are likely involved in lung cancer cell invasion through the surrounding stromal tissue, thus enhancing formation of metastases

Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation

After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014. Although it is a significant achievement to see the first asset being placed into human trials under an adaptive pathway, there is much to be learned regarding the multinational and multi-stakeholder effort that has driven the growing acceptance of MAPPs as a methodology and concept, as well as the need for continued and increasing international collaboration to foster the wider adoption of MAPPs. Changes in available science and technology, as well as a number of challenges in the current system, outlined in this paper, are transforming approaches to medicines development and approval. It is these challenges that have led directly to the groundbreaking MAPPs collaboration between the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms Initiative, the EMA, patient, payer and health technology assessment groups, the European Federation of Pharmaceutical Industries and Associations, and the Innovative Medicines Initiative—a European public-private partnership. This article examines the development of MAPPs, from inception of the concept, to the establishment of this trans-Atlantic initiative, and examines challenges for the future.SCOPUS: ar.jinfo:eu-repo/semantics/publishe